Such a vaccine can provide a significant advantage, especially in developing countries, in that its administration does not require medical skill, the logistics for its transportation are simpler and cheaper and should even cover a wide range of variants
The Catalent company, which provides development and production services to pharmaceutical companies, located in New Jersey, and also has laboratories in England, and the Israeli company MigVax, which develops an oral subunit vaccine against Corona, signed an agreement to use Catalent's unique technology - Zydis Bio, for the production of a soluble tablet in space The mouth, which will be integrated into the development of the vaccine, within the framework of Migvax's cooperation with the international organization CEPI, in order to develop an oral vaccine in a tablet against the corona virus and its many variants.
The vaccine developed by Migvax showed promising results in pre-clinical trials, which proved the effectiveness of the oral vaccine as a booster vaccine. The uniqueness of the vaccine is the way it is given in a soluble tablet in the oral cavity, which can be a significant advantage, especially in developing countries, in that its administration does not require medical skill, the logistics for its transportation are simpler and cheaper and should even cover a wide range of variants. In addition, this form of oral administration may create an immune response in the mucous membranes and provide unique protection where the virus enters the body.
Catalent's technology is a freeze-dried tablet that dissolves quickly in the oral cavity without the need for water. This technology is one of the most advanced in the world in its field and provides substantial advantages over more traditional forms of oral administration, such as: higher patient compliance, product durability and convenience. Therefore, this technology is very effective in the oral administration of macromolecules.
As part of the agreement, Catalent performed proof of programming for the combination of Migvax's vaccine compounds with its unique tablet formula as well as an evaluation of the tablet's effectiveness and stability. This work was carried out in the company's laboratories in Great Britain. Migvax started a pre-clinical trial to test the effectiveness of the tablet vaccine.
Ran Amir, CEO of Migvax: "We are excited to collaborate with Catalent in order to optimize the logistics, storage and form of administration of the Migvax vaccine. A tablet vaccine, combined with Catalent's technology, which will be transported without the need for refrigeration but through a standard supply chain, will greatly facilitate its widespread distribution to all parts of the world. We believe that this will be a significant step in how human society copes with the effort to return to normality and life alongside the corona." According to Jonathan Arnold, president of the department of oral products and unique routes of administration at Catalent: "Catalent's unique technology brings several advantages to Migwax's development program in that it is a proven technology that has been successfully used to create antibodies in the mucosa. In addition, the simplicity of the method of administration and the potential to simplify the supply chain due to the fact that there is no need for frozen transportation will lead to the reduction of logistical barriers and the expansion of the distribution of vaccines."
